Physician profile
Ashraf N Nashed
NPI 1144290081
$22,686.59
in general payments reported to CMS, 2019-2025
51 companies · $2,232 in 2025
The $2,232 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,366 · 2020: $2,288 · 2021: $2,310 · 2022: $5,485 · 2023: $1,861 · 2024: $4,144 · 2025: $2,232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,069 · Travel and Lodging: $2,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,068.54 |
| Travel and Lodging | $2,168.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $4,201.30 | 2022-2025 | (6554) Peripheral Vascular Undivided, Coronary Undivided, Igt Devices Undivided |
| Abbott Laboratories | $2,985.36 | 2019-2024 | Xact, Assurity, Aveir |
| Biotronik INC. | $1,999.54 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $1,974.50 | 2019-2025 | Farxiga, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,244.03 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $1,213.62 | 2019-2025 | |
| Amarin Pharma, INC. | $927.34 | 2019-2023 | |
| Cvrx, INC. | $863.46 | 2024 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $858.58 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $739.34 | 2019-2025 | Verquvo, Belsomra |
| Lilly USA, LLC | $586.19 | 2019-2025 | Mounjaro, Zepbound |
| Amgen INC. | $564.37 | 2019-2025 | Repatha, Repatha |
| Cardiovascular Systems INC. | $461.03 | 2022 | |
| Janssen Pharmaceuticals, INC | $410.97 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $348.78 | 2019-2023 | Uptravi, Opsumit |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashraf Nashed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.